Back to top

gene-editing: Archive

Zacks Equity Research

SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion

Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.

RHHBYNegative Net Change SRPTNegative Net Change AGENNegative Net Change IMCRPositive Net Change

Sundeep Ganoria

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?

CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.

VRTXPositive Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change

Zacks Equity Research

FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector

With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same gene-delivery method.

RHHBYNegative Net Change SRPTNegative Net Change AGENNegative Net Change IMCRPositive Net Change

Sundeep Ganoria

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.

BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change